Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Research provides a roadmap for new therapies to treat chorioamnionitis

Research provides a roadmap for new therapies to treat chorioamnionitis

Intensive treatment for patients with Crohn's disease found to be safe

Intensive treatment for patients with Crohn's disease found to be safe

Biosimilars could drive down drug prices and lead to $38.4 billion savings

Biosimilars could drive down drug prices and lead to $38.4 billion savings

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Patient support program for painful conditions may also help avoid use of risky opioids

Patient support program for painful conditions may also help avoid use of risky opioids

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

New trial to evaluate anti-TNF drug as a treatment for COVID-19 patients begins

New trial to evaluate anti-TNF drug as a treatment for COVID-19 patients begins

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

People suffering from rheumatoid arthritis with increased disease activity have high thrombosis risk

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

New study to evaluate drug combination treatment for uveitis

New study to evaluate drug combination treatment for uveitis

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Work in progress on medicine for treatment of ulcerative colitis

Work in progress on medicine for treatment of ulcerative colitis

Study identifies genetic marker which could personalize treatment for Crohn's disease

Study identifies genetic marker which could personalize treatment for Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease

Common genetic variant explains why immunotherapy often fails in Crohn's disease